目的 研究甲磺酸阿帕替尼片聯(lián)合紫杉醇注射液對(duì)非小細(xì)胞肺癌患者的療效及血清因子的影響。方法 選擇2013年3月-2018年3月在榆林市第一醫(yī)院腫瘤診療中心治療的80例非小細(xì)胞肺癌患者為研究對(duì)象，按照隨即數(shù)字法分為對(duì)照組和觀察組，每組各40例。對(duì)照組患者給予紫杉醇注射液?jiǎn)嗡幓煟?75 mg/m²將紫杉醇溶于生理鹽水中稀釋，靜脈滴注3 h，每周1次。觀察組在對(duì)照組的基礎(chǔ)上口服甲磺酸阿帕替尼片，850 mg/次，1次/d。3周為1個(gè)療程，兩組均治療3個(gè)療程。觀察兩組化療后的臨床療效，比較兩組化療前后的血清因子水平，包括血管內(nèi)皮生長(zhǎng)因子（VEGF）、基質(zhì)金屬蛋白（MMP-9）、細(xì)胞角蛋白19片段（CYFRA21-1）和血清癌胚抗原（CEA）和化療期間不良反應(yīng)發(fā)生情況。結(jié)果 化療后，觀察組患者的總有效率為82.5%，顯著高于對(duì)照組的62.50%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）?；熀螅瑑山M患者VEGF、MMP-9、CYFRA21-1和CEA水平較治療前均顯著降低（P<0.05），且觀察組血清學(xué)指標(biāo)水平顯著低于對(duì)照組（P<0.05）。兩組在化療期間均出現(xiàn)白細(xì)胞減少、血小板減少、關(guān)節(jié)痛等不良反應(yīng)，且無(wú)顯著差異，給予對(duì)癥治療后均緩解。結(jié)論 甲磺酸阿帕替尼片聯(lián)合紫杉醇注射液化療對(duì)非小細(xì)胞肺癌療效較好，能有效改善患者血清學(xué)指標(biāo)，值得在臨床應(yīng)用和推廣。

Objective To investigate effect on clinical effect and serum factor in treatment of NSCLC patients by using Paclitaxel Injection combined with Apatinib Mesylate Tablets. Methods Selected 80 cases of patients with NSCLC who were treated in the cancer center of The First Hospital of Yulin from March 2013 to March 2018, divided into control (40 cases) and observation (40 cases) groups randomly. The control group was given Paclitaxel Injection single drug chemotherapy. 175 mg/m² paclitaxel was dissolved in normal saline, and intravenously dripped for 3 h, once a week. The observation group were po administered with Apatinib Mesylate Tablets on the basis of control group, 850 mg/time, once daily. 3 weeks is a course of treatment, both groups were treated for 3 courses. After chemotherapy, the clinical effect was evaluated, and serum factor levels (VEGF, MMP-9, CYFRA21-1 and CEA) and adverse reactions in two groups before and after chemotherapy were compared. Results After chemotherapy, the total effective rate of the observation group was 82.50%, significantly higher than 62.50% in the control group, and there was difference between two groups (P<0.05). After chemotherapy, the VEGF, MMP-9, CYFRA21-1 and CEA levels in two groups were significantly reduced (P<0.05), and the serological indexes in the observation group were lower than those in the control group (P<0.05). Both groups showed adverse reactions such as leukopenia, thrombocytopenia, and joint pain during chemotherapy, and were relieved after symptomatic treatment without significant difference. Conclusion Paclitaxel Injection combined with Apatinib Mesylate Tablets is effective in treatment of NSCLC. It can effectively improve the serological indexes of patients, and is worthy of clinical application and promotion.